<DOC>
	<DOCNO>NCT02034331</DOCNO>
	<brief_summary>Persons spinal cord injury ( SCI ) increase risk metabolic disorder , include insulin resistance . As result neurological injury , often impaired mechanism regulate blood vessel function level injury . Insulin , facilitate transport glucose muscle cell , also capable regulate skin blood flow , insulin resistance reduce perfusion . Although beyond scope proposal , possibility exists impair microvascular skin blood flow response due insulin may predispose ischemia skin pressure point bony prominence . This perturb cutaneous vascular response may place person SCI risk development poor healing pressure ulcer due microvascular dysfunction secondary neurologic metabolic disorder . Primary Aim : To determine association systemic insulin sensitivity insulin-mediated vasodilatation neurological level injury . We hypothesize individual systemic insulin sensitivity compare insulin resistance great insulin-mediated vasodilatation associate proportional increase cutaneous blood perfusion . Thus , intact appropriate endothelial-mediated regulation insulin operative despite sub-lesional neurological impairment insulin sensitive individual SCI . However , absence SNS-mediated insulin action microvasculature ( i.e. , insulin-mediated sympathetic withdrawal ) , hypothesize vasodilatory response iontophoresis insulin insulin sensitive subject SCI less observe neurologically intact control insulin sensitivity . Secondary Aim : To compare peak microvascular perfusion responses endothelial-dependent vasodilatation iontophoresis acetylcholine insulin . We hypothesize peak blood perfusion response iontophoresis insulin comparable magnitude acetylcholine individual great systemic insulin sensitivity . This contrast individual systemic insulin resistance demonstrate diminish response iontophoresis insulin compare acetylcholine . Because SNS impairment , peak vasodilatory response observe intervention low group SCI .</brief_summary>
	<brief_title>IR Microvascular Blood Flow SCI</brief_title>
	<detailed_description>Cutaneous microvascular blood flow regulate multiple mechanism , include insulin sympathetic nervous system ( SNS ) . Insulin principal hormone responsible disposal storage glucose skeletal muscle , part re-direction blood flow rhythmic dilatation contraction arteriole . In insulin-sensitive individual , `` vasomotion '' think involve activation vascular smooth muscle , vasodilatation occur nitric oxide vasoconstriction SNS endothelin-1 . A tonic upregulation SNS activity increase vasoconstrictor action insulin may contributor development hypertension , decreased peripheral blood flow , endothelial dysfunction general population , especially individual hyperinsulinemia diabetes mellitus . In person spinal cord injury ( SCI ) , disproportionately high prevalence insulin resistance diabetes mellitus report . We postulate insulin resistance , combination add consequence SNS impairment neurological level injury , contribute hemodynamic dysregulation variety medical complication , include pressure ulcer formation decrease wound heal . Recently , group demonstrate sub-lesional blood perfusion response iontophoresis insulin blunt euinsulinemic person motor-complete SCI compare demographics-matched neurologically-intact control subject . To confirm extend preliminary find provide additional insight implication , propose perform open-label , non-randomized , placebo-controlled , parallel-group intervention , observational trial determine hemodynamic action insulin individual complete motor lower extremity paralysis due SCI either systemic insulin sensitivity insulin resistance . Subjects participate screen visit determine eligibility insulin sensitivity ( i.e. , categorize insulin-sensitive insulin-resistant ) . Eligible individual return participation study determine skin blood flow iontophoresis vasoactive agent application heat extremity . Measurements perform simultaneously provocation ( i.e. , either heat insulin acetylcholine iontophoresis ) perform ipsilateral extremity provocative intervention ( i.e. , either heat placebo iontophoresis ) parallel simultaneously contralateral extremity . On separate visit , subject repeat iontophoresis acetylcholine , gold-standard induce endothelium-dependent vasodilatation microvasculature . After screen , subject participate 2 study visit iontophoresis ( i.e. , placebo , insulin , acetylcholine ) heat provocation perform one time upper one time low extremity . Each study visit take 4 hour . The expected enrollment time participant complete study 3 week . The respective outcome iontophoresis insulin compare correlated systemic insulin sensitivity ( determine intravenous glucose tolerance test insulin administration ) ( Primary Aim ) . The peak microvascular perfusion response vasodilatation iontophoresis acetylcholine insulin compare ( Secondary Aim ) . In participant SCI , finding neurologically intact upper extremity compare neurologically impaired low extremity ( Tertiary Aim ) . A group neurologically-intact subject match group assignment ( i.e. , insulin-sensitive insulin resistant ) serve age- gender-matched control participant SCI .</detailed_description>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Acetylcholine</mesh_term>
	<criteria>1 . Male female , age 20 69 ; 2 . Chronic ( e.g. , duration injury least 6 month ) , stable SCI ( regardless level neurological lesion ) ; 3 . American Spinal Injury Association Impairment Scale ( AIS ) designation A B ( reflect level somatosensory impairment neurological level injury : AIS A complete sensory motor lesion ; AIS B incomplete sensory complete motor lesion ) ; 4 . Neurologically intact , agematched control subject 5. insulinsensitive group : Si ≥ 2.5 min1 ∙ mU1 ∙ L x 104 ; 6. insulin resistant group : Si &lt; 2.5 min1 ∙ mU1 ∙ L x 104 1 . Diminished mental capacity ; 2 . Inability unwillingness subject provide inform consent ; 3 . Acute illness infection ; 4 . Current pharmacological treatment diabetes mellitus insulin resistance exogenous insulin ( synthetic dialogue ) , insulinsensitizing agent , agent alter pancreatic secretion insulin ; 5 . Current pharmacological treatment sympathomimetic agent demonstrate direct vascular action indirect implication ( e.g. , alpha1 agonist , cholinesterase inhibitor , norepinephrine , calcium channel blocker , angiotensin convert enzyme ) ; 6 . Moderate high dose glucocorticoid administration ( i.e. , ≥ 40mg prednisone equivalent steroid dose ) within past 3 month ; 7 . Atherosclerosis , congestive heart failure , history myocardial infarction ; 8 . Previous diagnosis diabetes mellitus insulin resistance ; 9 . AIS designation C , D E ( SCI subject ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Insulin Sensitivity</keyword>
	<keyword>Microvascular permeability</keyword>
	<keyword>Sympathetic nervous system</keyword>
</DOC>